CancerDrs

Head and Neck Cancer clinical trials in Virginia

45 actively recruiting head and neck cancer trials at 21 sites across Virginia.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 1 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 2, Phase 3 Recruiting NIH

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins i…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT01810913
Sites in Virginia:
  • Inova Fairfax Hospital — Falls Church, Virginia
  • Sentara Cancer Institute at Sentara CarePlex Hospital — Hampton, Virginia
  • Sentara Norfolk General Hospital — Norfolk, Virginia
  • VCU Massey Comprehensive Cancer Center — Richmond, Virginia
  • Sentara Virginia Beach General Hospital — Virginia Beach, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) a…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06589804
Sites in Virginia:
  • VCU Massey Cancer Center at Stony Point — Richmond, Virginia
  • VCU Massey Comprehensive Cancer Center — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor recept…

Sponsor: AstraZeneca
NCT ID: NCT07431281
Sites in Virginia:
  • Research Site — Blacksburg, Virginia
  • Research Site — Fairfax, Virginia
  • Research Site — Falls Church, Virginia
  • Research Site — Fort Belvoir, Virginia
  • Research Site — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.

Sponsor: Merus B.V.
NCT ID: NCT06496178
Sites in Virginia:
  • Site 10 — Blacksburg, Virginia
  • Site 22 — Charlottesville, Virginia
  • Site 156 — Winchester, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

The purpose of this study is to compare anti-tumor activity of amivantamab in addition to pembrolizumab and carboplatin versus pembrolizumab, 5-fluorouracil (FU), and platinum therapy (carboplatin or cisplatin) in participants with refract…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07276399
Sites in Virginia:
  • University of Virginia — Charlottesville, Virginia
  • Virginia Cancer Specialists — Fairfax, Virginia
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

The goal of this study is to assess the safety and effectiveness of Dostarlimab compared to Placebo in adult participants with Head and Neck Squamous Cell Carcinoma (HNSCC)

Sponsor: GlaxoSmithKline
NCT ID: NCT06256588
Sites in Virginia:
  • GSK Investigational Site — Fredericksburg, Virginia
  • GSK Investigational Site — Wytheville, Virginia
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study

This phase II trial studies the good and bad effects of the combination of drugs called cabozantinib and nivolumab in treating patients with melanoma or squamous cell head and neck cancer that may have spread from where it first started to…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05136196
Sites in Virginia:
  • Inova Alexandria Hospital — Alexandria, Virginia
  • Inova Schar Cancer Institute — Fairfax, Virginia
  • Inova Fair Oaks Hospital — Fairfax, Virginia
  • Inova Fairfax Hospital — Falls Church, Virginia
  • Centra Alan B Pearson Regional Cancer Center — Lynchburg, Virginia
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

This phase II trial compares the effectiveness of adding BMX-001 to usual symptom management versus usual symptom management alone for reducing oral mucositis in patients who are receiving chemoradiation for head and neck cancer. Oral muco…

Sponsor: NRG Oncology
NCT ID: NCT06532279
Sites in Virginia:
  • VCU Massey Cancer Center at Stony Point — Richmond, Virginia
  • VCU Massey Comprehensive Cancer Center — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer

This phase II trial tests how well nivolumab and ipilimumab immunotherapy with or without cabozantinib works in treating patients with nasopharyngeal cancer that has come back (after a period of improvement) (recurrent), has spread from wh…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05904080
Sites in Virginia:
  • VCU Massey Cancer Center at Stony Point — Richmond, Virginia
  • VCU Massey Comprehensive Cancer Center — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06064097
Sites in Virginia:
  • University of Virginia Cancer Center — Charlottesville, Virginia
  • Children's Hospital of The King's Daughters — Norfolk, Virginia
  • VCU Massey Comprehensive Cancer Center — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…

Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in Virginia:
  • Virginia Cancer Specialists — Fairfax, Virginia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.

Sponsor: Revolution Medicines, Inc.
NCT ID: NCT06128551
Sites in Virginia:
  • NEXT Oncology Virginia — Fairfax, Virginia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

This study, the first clinical trial of AVZO-1418, aims to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, maximum tolerated dose, and antitumor activity of AVZO-1418 when administered intravenously as a monotherapy…

Sponsor: Avenzo Therapeutics, Inc.
NCT ID: NCT07038343
Sites in Virginia:
  • Avenzo Therapeutics Recruiting Site — Fairfax, Virginia
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…

Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in Virginia:
  • Virginia Cancer Specialists — Fairfax, Virginia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

The purpose of this study is to determine safety and preliminary efficacy of amivantamab monotherapy, amivantamab in addition to pembrolizumab, amivantamab in addition to paclitaxel and amivantamab in addition to pembrolizumab and carbopla…

Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06385080
Sites in Virginia:
  • University of Virginia — Charlottesville, Virginia
  • Virginia Cancer Specialists — Fairfax, Virginia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alteratio…

Sponsor: Terremoto Biosciences Inc.
NCT ID: NCT07109726
Sites in Virginia:
  • NEXT Oncology — Fairfax, Virginia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies …

Sponsor: Institut de Recherches Internationales Servier
NCT ID: NCT05786924
Sites in Virginia:
  • NEXT Virginia — Fairfax, Virginia
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

DESTINY-Gastric03 will investigate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of trastuzumab deruxtecan (T-DXd) alone or in combination with chemotherapy and/or immunotherapy in HER2-expr…

Sponsor: AstraZeneca
NCT ID: NCT04379596
Sites in Virginia:
  • Research Site — Fairfax, Virginia
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

This is a Phase 1/2a, open-label, study to evaluate the safety and preliminary efficacy of intratumoral T3011 given alone and in combination with intravenous pembrolizumab in partients with advanced or metastatic solid tumors.

Sponsor: ImmVira Pharma Co. Ltd
NCT ID: NCT04370587
Sites in Virginia:
  • Virginia Cancer Specialists — Fairfax, Virginia
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

This phase II trial compares the effectiveness of cemiplimab with CDX-1140 to cemiplimab without CDX-1140 prior to surgery in treating patients with stage III-IV head and neck cancer. Immunotherapy with monoclonal antibodies, such as cemip…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06980038
Sites in Virginia:
  • VCU Massey Comprehensive Cancer Center — Richmond, Virginia
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer

Background: Cisplatin is used to treat head and neck cancer. People who take this drug are at risk for hearing loss. Atorvastatin is a drug used to treat high cholesterol. It might reduce the risk of cisplatin-induced hearing loss. Objecti…

Sponsor: National Institute on Deafness and Other Communication Disorders (NIDCD)
NCT ID: NCT04915183
Sites in Virginia:
  • Inova Schar Cancer Center — Fairfax, Virginia
View on ClinicalTrials.gov →

Showing 25 of 45 trials with sites in Virginia. See all head and neck cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-06-15